136 related articles for article (PubMed ID: 28781506)
1. David B. Nash Advocates Better Outcomes And Lower Costs Through Population Health.
McIver JS
P T; 2017 Aug; 42(8):522-526. PubMed ID: 28781506
[TBL] [Abstract][Full Text] [Related]
2. Interview with a quality leader: Dr. David Nash. Interviewed by Kathleen Tornow Chai.
Nash DB
J Healthc Qual; 2013; 35(1):18-20. PubMed ID: 23281635
[TBL] [Abstract][Full Text] [Related]
3. The Economic Burden of Non-Alcoholic Steatohepatitis: A Systematic Review.
Witkowski M; Moreno SI; Fernandes J; Johansen P; Augusto M; Nair S
Pharmacoeconomics; 2022 Aug; 40(8):751-776. PubMed ID: 35789987
[TBL] [Abstract][Full Text] [Related]
4. Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
O'Hara J; Finnegan A; Dhillon H; Ruiz-Casas L; Pedra G; Franks B; Morgan G; Hebditch V; Jönsson B; Mabhala M; Reic T; Van Thiel I; Ratziu V; Romero-Gomez M; Bugianesi E; Schattenberg JM; Anstee QM
JHEP Rep; 2020 Oct; 2(5):100142. PubMed ID: 32775976
[TBL] [Abstract][Full Text] [Related]
5. Comorbidities and healthcare costs and resource use of patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in the Japan medical data vision database.
Terai S; Buchanan-Hughes A; Ng A; Lee IH; Hasegawa K
J Gastroenterol; 2021 Mar; 56(3):274-284. PubMed ID: 33496858
[TBL] [Abstract][Full Text] [Related]
6. Ethics and the 'seasons of my life' as a dental educator.
Nash DA
J Am Coll Dent; 2011; 78(3):18-23. PubMed ID: 22263366
[TBL] [Abstract][Full Text] [Related]
7. The Jefferson Medical College and the International Medical Congress-Letter from Dr. Roberts Bartholow, Dean.
Bartholow R
Daniels Tex Med J; 1886 Sep; 2(3):112-114. PubMed ID: 36952692
[No Abstract] [Full Text] [Related]
8. Lessons Learned by a Founding Dean: College of Health and Human Services at Western Kentucky University.
Bonaguro JA
J Allied Health; 2017; 46(4):269-273. PubMed ID: 29202164
[TBL] [Abstract][Full Text] [Related]
9. WILLIAM A. SODEMAN, M.D., DEAN JEFFERSON MEDICAL COLLEGE.
Pa Med J; 1964 May; 67():19-23. PubMed ID: 14146259
[No Abstract] [Full Text] [Related]
10. Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand.
Phisalprapa P; Prasitwarachot R; Kositamongkol C; Hengswat P; Srivanichakorn W; Washirasaksiri C; Treeprasertsuk S; Charatcharoenwitthaya P; Chaiyakunapruk N
BMC Gastroenterol; 2021 Mar; 21(1):135. PubMed ID: 33765931
[TBL] [Abstract][Full Text] [Related]
11. An Interview with David B. Nash, MD, MBA: a perspective on population health and the future direction of healthcare.
Persichilli JM; Puro JS
MD Advis; 2017; 10(4):33-36. PubMed ID: 29286602
[No Abstract] [Full Text] [Related]
12. Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain.
Romero-Gomez M; Kachru N; Zamorano MA; Darba J; Shreay S
Medicine (Baltimore); 2020 Dec; 99(50):e23506. PubMed ID: 33327291
[TBL] [Abstract][Full Text] [Related]
13. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Dobrić I
Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
[TBL] [Abstract][Full Text] [Related]
14. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes.
Younossi Z; Aggarwal P; Shrestha I; Fernandes J; Johansen P; Augusto M; Nair S
JHEP Rep; 2022 Sep; 4(9):100525. PubMed ID: 36039144
[TBL] [Abstract][Full Text] [Related]
15. Real-world Comorbidity Burden, Health Care Utilization, and Costs of Nonalcoholic Steatohepatitis Patients With Advanced Liver Diseases.
Wong RJ; Kachru N; Martinez DJ; Moynihan M; Ozbay AB; Gordon SC
J Clin Gastroenterol; 2021 Nov-Dec 01; 55(10):891-902. PubMed ID: 32815873
[TBL] [Abstract][Full Text] [Related]
16. Steps towards establishing a new medical college in the Kingdom of Saudi Arabia: an insight into medical education in the Kingdom.
Bin Abdulrahman KA; Saleh F
BMC Med Educ; 2015 May; 15():85. PubMed ID: 25943402
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).
Harrison SA; Thang C; Bolze S; Dewitt S; Hallakou-Bozec S; Dubourg J; Bedossa P; Cusi K; Ratziu V; Grouin JM; Moller DE; Fouqueray P
J Hepatol; 2023 May; 78(5):914-925. PubMed ID: 36804402
[TBL] [Abstract][Full Text] [Related]
18. Disease Severity Is Associated With Higher Healthcare Utilization in Nonalcoholic Steatohepatitis Medicare Patients.
C Gordon S; Fraysse J; Li S; Ozbay AB; Wong RJ
Am J Gastroenterol; 2020 Apr; 115(4):562-574. PubMed ID: 31833859
[TBL] [Abstract][Full Text] [Related]
19. Burden of Illness and Economic Model for Patients With Nonalcoholic Steatohepatitis in the United States.
Younossi ZM; Tampi R; Priyadarshini M; Nader F; Younossi IM; Racila A
Hepatology; 2019 Feb; 69(2):564-572. PubMed ID: 30180285
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
